Watson to sell ScinoPharm share to Uni-President

By Gareth Macdonald

- Last updated on GMT

Related tags Investment Pharmaceutical drug

A significant share of contract API maker ScinoPharm Taiwan is set to change hands after Watson Pharmaceuticals decided to sell its stake to Uni-President Enterprises Corporation.

New Jersey, US based generics manufacturer Watson invested $15.3m in ScinoPharm in 2004 to expand its access to the specialist active pharmaceutical ingredients (API) the Taiwanese produces.

Over the next few years Watson gradually increased its shareholding, spending $19.4m in 2005 and a further $12m the following year until it owned just under a third, 31 per cent, of the API maker.

However, according to CEO Paul Bisaro, while the investment strategy has been effective in securing API supplies, Watson has now increased in-house capabilities to a point where the deal with ScinoPharm is no longer the best option for “long-term growth​.”

Watson predicted that the divestiture, which is subject to Taiwanese government approval, will generate net proceeds of approximately $94.0 million and said that the deal will close later this year.

Taiwanese food conglomerate Uni-President Enterprises Corporation already owns a substantial share of ScinoPharm and was a significant investor in ScinoPharm when the company was set up in the late 90s.

Capacity expansion

Watson's capacity expansion began in 2004 when it purchased a pharmaceutical manufacturing plant in Goa, India from Dr Reddy's Laboratories.

The following year​ the US non-branded drugmaker acquired Indian contract manufacturing organisation (CMO) Sekhsaria Chemicals, in a move specifically focused on adding API production capacity.

And, late last year, Watson further expanded capacity with the purchase of fellow non-branded drugmaker Arrow Group​. This deal also gave the firm a 35 per cent stake in UK contract biologics maker Eden Biodesign.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us